Platinum (Pt) compounds entered the clinic as anticancer agents when cisplatin was
approved in 1978. More than 40 years later, even in the era of precision medicine and …

Over the past 20 years, there has been considerable progress in our understanding of the
biological functions of the BRCA1 and BRCA2 cancer susceptibility genes. This has led to …

Abstract Approximately 1–5% of breast cancers are attributed to inherited mutations in
BRCA1 or BRCA2 and are selectively sensitive to poly (ADP-ribose) polymerase (PARP) …

The efficacy of programmed cell death protein 1 (PD-1) blockade in metastatic triple-
negative breast cancer ( TNBC) is low,,,–, highlighting a need for strategies that render the …

Defective DNA repair is a common hallmark of cancer. Homologous recombination is a DNA
repair pathway of clinical interest due to the sensitivity of homologous recombination …

Cellular responses to DNA damage are important determinants of both cancer development
and cancer outcome following radiation therapy and chemotherapy. Identification of …

Breast cancer is a heterogeneous disease. There is a high degree of diversity between and
within tumors as well as among cancer-bearing individuals, and all of these factors together …

BRCA1 inactivation is a frequent event in basal-like breast carcinomas (BLC). However,
BRCA1 can be inactivated by multiple mechanisms and determining its status is not a trivial …

Tumours with specific DNA repair defects can be completely dependent on back-up DNA
repair pathways for their survival. This dependence can be exploited therapeutically to …

Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancers. It is a
heterogeneous disease, not only on the molecular level, but also on the pathologic and …